-$0.08 EPS Expected for Tyme Technologies Inc (TYME) This Quarter

Wall Street analysts expect that Tyme Technologies Inc (NASDAQ:TYME) will announce ($0.08) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Tyme Technologies’ earnings. Tyme Technologies reported earnings per share of ($0.06) during the same quarter last year, which would indicate a negative year over year growth rate of 33.3%. The company is scheduled to issue its next quarterly earnings report on Wednesday, June 12th.

On average, analysts expect that Tyme Technologies will report full-year earnings of ($0.29) per share for the current fiscal year. For the next fiscal year, analysts forecast that the firm will report earnings of ($0.34) per share. Zacks Investment Research’s EPS averages are an average based on a survey of research analysts that cover Tyme Technologies.

Tyme Technologies (NASDAQ:TYME) last posted its quarterly earnings data on Monday, February 11th. The company reported ($0.08) earnings per share for the quarter, hitting the consensus estimate of ($0.08).

A number of analysts have commented on the stock. BidaskClub lowered shares of Tyme Technologies from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 5th. HC Wainwright set a $10.00 target price on shares of Tyme Technologies and gave the stock a “buy” rating in a report on Tuesday, February 26th. Finally, Zacks Investment Research lowered shares of Tyme Technologies from a “buy” rating to a “hold” rating in a report on Wednesday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $7.83.

In other news, Director Douglas A. Michels purchased 20,000 shares of the firm’s stock in a transaction dated Thursday, February 14th. The stock was bought at an average price of $3.26 per share, with a total value of $65,200.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 53.90% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in TYME. Wells Fargo & Company MN grew its holdings in shares of Tyme Technologies by 149.1% in the 3rd quarter. Wells Fargo & Company MN now owns 266,026 shares of the company’s stock valued at $739,000 after buying an additional 159,251 shares during the period. BlackRock Inc. grew its holdings in shares of Tyme Technologies by 3.6% in the 3rd quarter. BlackRock Inc. now owns 2,065,741 shares of the company’s stock valued at $5,744,000 after buying an additional 71,188 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Tyme Technologies in the 3rd quarter valued at $100,000. Vanguard Group Inc. grew its holdings in shares of Tyme Technologies by 60.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,865,160 shares of the company’s stock valued at $5,186,000 after buying an additional 699,871 shares during the period. Finally, Vanguard Group Inc grew its holdings in shares of Tyme Technologies by 60.1% in the 3rd quarter. Vanguard Group Inc now owns 1,865,160 shares of the company’s stock valued at $5,186,000 after buying an additional 699,871 shares during the period. 16.08% of the stock is owned by institutional investors.

TYME stock traded down $0.10 during trading on Friday, hitting $1.52. The company had a trading volume of 13,752 shares, compared to its average volume of 723,114. Tyme Technologies has a 12 month low of $1.57 and a 12 month high of $4.64. The stock has a market capitalization of $168.15 million, a PE ratio of -7.24 and a beta of 0.22.

Tyme Technologies Company Profile

Tyme Technologies, Inc, a clinical-stage biotechnology company, develops novel cancer therapeutics. It is developing SM-88, a combination therapy based on dysfunctional metyrosine derivatives in Phase II development for metastatic pancreatic cancer and biomarker-recurrent prostate cancer. The company was founded in 2011 and is headquartered in New York, New York.

Further Reading: How to Track your Portfolio in Google Finance

Get a free copy of the Zacks research report on Tyme Technologies (TYME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tyme Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyme Technologies and related companies with MarketBeat.com's FREE daily email newsletter.